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Abstract Mast cells are important effectors of type
I allergy but also essential regulators of innate and
adaptive immune responses. The aim of this study
was to develop a Cre recombinase-expressing mouse
line that allows mast cell-speciﬁc inactivation of
genes in vivo. Following a BAC transgenic approach,
Cre was expressed under the control of the mast
cell protease (Mcpt) 5 promoter. Mcpt5-Cre trans-
genic mice were crossed to the ROSA26-EYFP
Cre excision reporter strain. Efﬁcient Cre-mediated
recombination was observed in mast cells from the
peritoneal cavity and the skin while only minimal
reporter gene expression was detected outside the
mast cell compartment. Our results show that the
Mcpt5 promoter can drive Cre expression in a mast
cell-speciﬁc fashion. We expect that our Mcpt5-Cre
mice will be a useful tool for the investigation of mast
cell biology.
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Abbreviations
BAC Bacterial artiﬁcial chromosome
BMMC Bone marrow-derived mast cells
EYFP Enhanced yellow ﬂuorescent protein
FACS Fluorescence activated cell sorting
ﬂoxed loxP-ﬂanked
kb Kilobases
Mcpt Mast cell protease
HR Homology region
MACS Magnetic activated cell sorting
neo Neomycin resistance gene
SCF Stem cell factor
Introduction
Mast cells are central effector cells in type I allergy
(Kawakami and Galli 2002; Metcalfe et al. 1997), but
have recently been shown to be important initiators
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DOI 10.1007/s11248-007-9153-4and effectors also of innate immunity as well as
modulators of adaptive immune responses (Galli
et al. 2005a, b; Marshall and Jawdat 2004). Many
reports demonstrated a role of mast cells in host
defence against pathogens (Dawicki and Marshall
2007; Echtenacher et al. 1996; Malaviya et al. 1996)
and implicated a function of these cells in wound
healing, tissue remodeling and transplant tolerance
(Lu et al. 2006; Trautmann et al. 2000; Weller et al.
2006). A pathogenic role of mast cells was discussed
in rheumatoid arthritis, systemic sclerosis, multiple
sclerosis and atherosclerosis (Bachelet et al. 2006;
Irani et al. 1992; Lee et al. 2002; Secor et al. 2000;
Sun et al. 2007).
Investigation of mast cell biology was severely
hampered by the scarcity of these cells in tissues.
Experimental systems that have widely been used are
in vitro analysis of mast cell lines or mast cells
differentiated in vitro from bone marrow (BMMC).
In vivo analysis of the function of genes in mast cells
until today relied on the reconstitution of mast cell-
deﬁcient rodents with mast cells derived from bone
marrow or hematopoietic cells of gene-deﬁcient
animals or from gene-deﬁcient embryonic stem cells
(Kitamura et al. 1978; Nakano et al. 1985; Tsai et al.
2002, 2000). These systems yielded valuable infor-
mation, but suffer important limitations. In the mouse
lines kit
W/W-v and kit
W-sh/W-sh, which are commonly
used for reconstitution experiments, spontaneous
mutations of the kit gene coding region or its
regulatory elements result in reduced activity of the
kit receptor that controls development and survival of
mast cells (Galli et al. 2005b; Grimbaldeston et al.
2005). In addition to mast cell-deﬁciency, kit
W/W-v
animals are characterized by sterility, anemia,
absence of melanocytes and interstitial cells of Cajal,
a high incidence of dermatitis, papillomas of the
forestomach, gastric ulcers and dilation of the duo-
denum (Galli et al. 2005b). kit
W-sh animals, which
lately are being used instead of kit
W/W-v mice, seem to
feature a more narrow defect with deﬁciency for mast
cells, melanocytes, and interstitial cells of Cajal
(Grimbaldeston et al. 2005). The transfer of in vitro
cultivated mast cells into mast cell-deﬁcient animals
by intradermal, intraperitoneal or intravenous injec-
tions can result in mast cell numbers, which,
dependent on the route of cell transfer and the
anatomical site, can approach normal mast cell
density, but often remain considerably lower with
signiﬁcant variability (Grimbaldeston et al. 2005;
Tsai et al. 2005).
The Cre/loxP recombination system represents a
powerful tool that allows for conditional, e.g. cell
type-speciﬁc, inactivation of genes in the mouse
(Rajewsky et al. 1996). Since the ﬁrst description of
in vivo mutagenesis using the Cre/loxP system (Gu
et al. 1994), an impressive number of ﬂoxed mouse
lines has been generated. Herein, we report the ﬁrst
Cre transgenic line allowing mast cell-speciﬁc gene
inactivation in vivo.
Material and methods
Construction of the transgene and generation
of transgenic mice
The construct was based on a bacterial artiﬁcial
chromosome (BAC) encompassing the entire Mcpt5
gene. The BAC clone RP23-284A14 from the mouse
BAC library RPCI-23 (Osoegawa et al. 2000) was
obtained from RZPD (Deutsches Ressourcenzentrum
fu ¨r Genomforschung GmbH, Berlin, Germany). All
modiﬁcations were done by homologous recombina-
tion in E. coli (Zhang et al. 1998) and sequences of all
oligonucleotides used for construction by homologous
recombination are listed in Table 1. Neighbouring
genes contained in the BAC were excluded by
replacing several kb of DNA at both ends of the insert
by resistance genes (Fig. 1). In a next step, a modiﬁed
iCre (improved Cre, Shimshek et al. 2002) gene
cassette (Testa et al. unpublished) was inserted into
the Mcpt5 gene. The Cre cassette was ﬁrst assembled
with a loxm2-ﬂanked neomycin-resistance cassette
(neo) and ﬂanked by homology regions (HR) for
recombination into the Mcpt5 gene. This was done by
subcloning the Cre cDNA into a minimal vector
consisting of the origin of replication and a chloram-
phenicol resistance gene ampliﬁed from pACYC184
(New England Biolabs, Frankfurt, Germany). The
primers used for the ampliﬁcation contain the HRs for
both subcloning of Cre and insertion into the Mcpt5
gene (see Table 1). In a next step, the neomycin
cassette was inserted 30 of Cre and 50 of the Mcpt5 HR.
The HR-Cre-Neo-HR cassette was released from the
minimal vector by NotI digestion and recombined into
the BAC replacing the coding part of exon 1 of the
Mcpt5genefollowedbyCre-mediateddeletionofneo.
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123The construct was puriﬁed for pronucleus injection as
described by Sparwasser et al. (2004) with modiﬁca-
tions. Brieﬂy, the construct was separated from the
BAC backbone by NotI digest and puriﬁed by gel
electrophoresis and electroelution. Pronucleus injec-
tion was done by R. Naumann, MPI of Molecular Cell
BiologyandGenetics,Dresden,Germany.Genotyping
of Mcpt5-Cre transgenic mice was performed by PCR
(primers: Mcpt5-CreFor 50ACAGTGGTATTCCCG
GGGAGTGT, Mcpt5-CreRev 50 GTCAGTGCGTT
CAAAGGCCA). Founder mice were bred to the
ROSA26-EYFP reporter line (Srinivas et al. 2001)
and ﬁve to 15 week old mice were analyzed for
reporter gene expression. Animals were housed under
SPF conditions and all experiments were done accord-
ing to institutional guidelines.
Table 1 Primers used for transgene construction by homologous recombination
recombination
Step/
Template
Primer Primer  sequence 
T7HR-Amp-FOR 5’GCTTGACATTGTAGGACTATATTGCTCT
AATAAATTTGCGGCCGCTAATAGGTCTGA
CGCTCAGTGGAAC
shaving of the T7 
end of vector 
backbone
Template:
pBluescriptIIKS+ 
InsertHR-NotI-Amp-
REV
5’TGCCTGTTGGCCTGTGGGAGCCCAGCG
AGGTTGGGGCCAGCAGCGGGTGCGCGG
CCGCGTGCGCGGAACCCCTATTTG
InsertHR-NotI-Zeo-
FOR
5’GGGCAGAAAGGCTCAGAAGTTGAGACT
CAGCAGGGCCTCAGAAAGCTGGTGCGGC
CGCCTCCCTTGGAGCCTACCTAGACTCA
shaving of the 
SP6 end of 
vector backbone
Template:
psiRNA-hH1zeo
SP6HR-Zeo-REV 5’TTTCTATCCTCCCGAATTGACTAGTGGG
TAGGCCTGGCGGCCGCCTGGCCAATGCA
CTGACCTCCCACATTCCCTT
HR(3’End of 
Cre)subcloning-
HR(last 50bp of 
Mcpt5-Exon1)-NotI-
minimalVectorFOR
5’ACGCCTATTTTTATAGGTTAATGTCATGA
TAATAATGGTTTCTTAGACGTGTGAGTGC
TGGGGTCGCTCCCTCTCCAATCTGCAGG
GTCAGCTCCTAAAAGCGGCCGCGCCCTG
CACCATTATGTTCCGGA
sub-cloning of 
Cre
Template:
pACYA184 
HR(5’End of 
Cre)subcloning-
HR(50bp upstream of 
Mcpt5-ATG)-NotI-
minimalVectorREV
5’ACAGGGAGGGCAGGCAGGTTTTGATGC
ACAGTCAGCAGGTTGGACACCATATTTGG
GCCTTAGGCTTATTACTCCCAGCGGGCAG
GGGAGTGGCAGAGCTGCGGCCGCGCCC
GGCAGTACCGGCATAACCA
HR(3’End of Cre)-
loxm2-NeoFOR
5’ACGCCTATTTTTATAGGTTAATGTCATGA
TAATAATGGTTTCTTAGACGTATAACTTCG
TATATGGTTTCTTATACGAAGTTATCGGCC
GCATTCTACCGGGTAGG
insertion of neo 
Template:
pPGK-gb2-neo
HR(last 50bp of 
Mcpt5-Exon1)-loxm2-
NeoREV
5’TTTTAGGAGCTGACCCTGCAGATTGGAG
AGGGAGCGACCCCAGCACTCACATAACTT
CGTATAAGAAACCATATACGAAGTTATCG
CGTTTAAACGGCGCGCCGCACACAA
Oligonucleotides used for transgene construction by homologous recombination. The respective 50 bp homology regions (HR) were
included into the primers used for the ampliﬁcation of selection markers or the minimal vector
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123Flow cytometric analysis
Total splenocyte suspensions were separated into
lymphocyte and non-lymphocyte fractions by mag-
netic cell sorting (MACS, Miltenyi Biotec, Bergisch
Gladbach, Germany) using anti-CD3-Biotin (clone
145-2C11, BD Pharmingen), anti-Biotin MicroBeads,
anti-CD19 MicroBeads and LS MACS columns
(Miltenyi Biotec). Skin cell suspensions were
prepared from shaved abdominal skin plus one ear
pinna by mincing followed by an incubation with
2 mg/ml collagenase IV (Worthington Biochem.
Corporation, Lakewood, NJ, USA) at 37C. Cells in
peritoneal lavage as well as single cell suspensions
from skin and spleen were stained with phycoerythrin
(PE)-conjugated anti-CD3 (clone 145-2C11), anti-
CD19 (clone 1D3); anti-CD11c (clone HL3), anti-
CD45 (clone 30-F11) and anti-Siglec-F (clone E50-
2440) (all from BD Pharmingen) or anti-FceRIa-PE
(clone MAR-1), allophycocyanin (APC)-conjugated
anti-CD117 (clone 2B8) and anti-CD49b (clone
D95), F4/80-Biotin (clone BM8) and streptavidin-
PE (all from eBiosciences, SanDiego, CA) or anti-
Gr-1-PE (clone RB6-8C5) (Miltenyi Biotech). The
cells were analyzed on a FACSCalibur (BD
Biosciences).
Results
Transgene construction and screening
of transgenic mice for Cre expression
In order to drive Cre expression in mast cells, we
used a BAC clone containing the entire Mcpt5 gene
along with abundant upstream and downstream
ﬂanking DNA (Fig. 1). Neighboring genes were
excluded by shortening the BAC on both ends to
avoid possible effects of altered gene dosage in the
transgenic mice. In a next step, the coding part of the
Fig. 1 Strategy of transgene construction. The BAC RP23-
284A14 was shortened by replacing 51.3 kb of insert DNA at
the T7 end of the vector backbone and 42.4 kb at the SP6 end
by an ampicillin (Amp) and zeocin (Zeo) resistance cassette,
respectively, resulting in a residual insert length of 129 kb. A
NotI restriction site was inserted along with each of the
resistance genes. The coding part of the ﬁrst exon of Mcpt5 was
replaced by a cassette comprising the Cre cassette and a loxm2-
ﬂanked neomycin resistance cassette (Neo) by homologous
recombination and subsequent deletion of neo by Cre-mediated
deletion in E. coli.( NotI, N, EcoRI, I, arrows represent open
reading frames, shaded boxes represent untranslated regions)
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123ﬁrst exon of Mcpt5 was replaced by the Cre cassette
(see Methods and Fig. 1). The construct was released
from the BAC backbone by NotI digest (Fig. 1) and
injected into the pronuclei of C57BL/6 oocytes. Six
Mcpt5-Cre transgenic founder animals were obtained
and mated to a ROSA26 reporter line (Srinivas et al.
2001) which expresses enhanced yellow ﬂuorescent
protein (EYFP) under the control of the ubiquitous
ROSA26 promoter following Cre-mediated deletion
of a loxP-ﬂanked stop element. Mcpt5-Cre ROSA26-
EYFP double transgenic animals were analyzed for
EYFP expression in peritoneal and skin mast cells by
FACS as described below (Fig. 2). Reporter gene
expression was detected in mast cells from three of
the six founder lines. One of these lines showed
EYFP expression in only 80% of peritoneal mast cells
and was not investigated further. Close to 100% of
peritoneal mast cells were EYFP positive in two
lines, which, because of autosomal inheritance of the
transgene in one line and X-linked inheritance in the
other, were called ‘‘A-Mcpt5-Cre’’ and ‘‘X-Mcpt5-
Cre’’, respectively.
Efﬁcient and mast cell-speciﬁc Cre-mediated
recombination in the lines A-Mcpt5-Cre
and X-Mcpt5-Cre
Highly efﬁcient Cre-mediated activation of reporter
gene expression was uniformly observed in peritoneal
CD117
+FceRIa
+ mast cells of seven A-Mcpt5-Cre
ROSA26-EYFP double transgenic animals (98.7–
99.6%, on average 99.1%, Fig. 2). In skin cell
suspensions mast cells were detected in extremely
low numbers, on average 0.32%. (Skin mast cells
were deﬁned as CD117
+CD45
+ cells. A staining of
FceRIa on skin mast cells was not reliable in our
hands, likely due to loss of epitopes after enzymatic
tissue digestion). In the ﬁve animals for which this
mast cell population was investigated, the majority of
the few CD117
+CD45
+ cells gated was EYFP
positive (43/47, 54/64, 32/39, 23/27 and 77/88 gated
events, Fig. 2). Given that the mast cell gate will
inevitably collect also some non-mast cells upon
analysis of high total cell numbers (40,000 events),
the percentage of skin mast cells expressing EYFP is
probably close to 100%. A similar efﬁciency of Cre-
mediated activation of the reporter gene was
observed in three male X-Mcpt5-Cre mice (not
shown) whereas the two female animals analyzed
showed EYFP ﬂuorescence in only 61% and 32% of
peritoneal mast cells consistent with random X-
chromosome inactivation (not shown).
In both lines, Cre-mediated activation of EYFP
expression was speciﬁc for mast cells. In seven
A-Mcpt5-Cre and three male X-Mcpt5-Cre animals
we detected no or only minimal numbers (i.e. below
1%) of EYFP positive cells (below 3% in one A-
Mcpt5-Cre animal) in hematopoietic populations
other than mast cells (Fig. 3) or in non-hematopoietic
cells of the skin cell suspensions (primarily kerati-
nocytes and ﬁbroblasts, not shown). As a control, we
used mice with germline deletion of the stop element
of the ROSA26-EYFP Cre excision reporter demon-
strating that all non-mast cell populations analysed
for reporter expression in Mcpt5-Cre mice can, in
principle, express EYFP (not shown). In contrast to
the seven A-Mcpt5-Cre mice (described above)
showing mast cell-speciﬁc Cre-mediated recombina-
tion, one A-Mcpt5-Cre mouse displayed non-speciﬁc
reporter gene expression in 15–25% of all cell types
analyzed including non-hematopoietic cells of the
skin (not shown). This ﬁnding likely reﬂects
Fig. 2 Efﬁciency of Cre-mediated reporter gene activation in
mast cells. EYFP expression is demonstrated in cells from
peritoneal lavage ﬂuid and single cell suspensions of skin of
Mcpt5-Cre ROSA26-EYFP double transgenic mice. Peritoneal
mast cells were stained for CD117 and FceRIa (n = 7) and
skin mast cells for CD117 and CD45 (n = 4). Mast cell
populations were gated and their EYFP ﬂuorescence displayed
in histogram plots. The black graph represents Mcpt5-Cre
ROSA26-EYFP double transgenic mice, the shaded graph
represents the Cre-negative but ROSA26-EYFP-positive con-
trol (littermates in most instances)
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123accidental early activity of the transgenic Mcpt5
promoter.
Absence of signiﬁcant Cre-mediated genotoxicity
in mast cells of Mcpt5-Cre animals
In order to exclude a reduced proliferative potential
of mast cells in Mcpt5-Cre transgenic mice due to
Cre-mediated genotoxic effects, we compared the
percentage of mast cells in peritoneal lavage and the
proliferation of peritoneal mast cells from Mcpt5-Cre
ROSA26-EYFP double transgenic or wild-type mice
in vitro. Cell suspensions obtained by peritoneal
lavage contained similar numbers of mast cells in
wild-type and double transgenic mice (Fig. 4a). Total
peritoneal lavage cells were cultured in the presence
of stem cell factor. After 23 days, these cultures
contained 98% mast cells as judged by expression of
CD117 and FceRIa (not shown). By this time,
absolute cell numbers had increased more than 200-
fold in both cultures (Fig. 4b). Importantly, the mast
cells grown from the Mcpt5-Cre ROSA26-EYFP
positive mouse uniformly expressed EYFP (not
shown) ruling out an overgrowth of the culture by a
(hypothetical) minor population of mast cells, which
do not express Cre. These results show that Mcpt5-
Cre positive mast cells are not growth retarded and
therefore do not seem to be signiﬁcantly affected by
Cre-mediated genotoxicity.
Discussion
Here, we describe a novel Cre transgenic mouse
allowing mast cell-speciﬁc knock out of genes
Fig. 3 Absence of EYFP
reporter gene expression in
hematopoietic cells other
than mast cells. EYFP
expression was analyzed in
hematopoietic cells from
peritoneal lavage and spleen
cell suspensions of Mcpt5-
Cre ROSA26-EYFP double
transgenic mice. In order to
enrich granulocytes,
splenocytes were separated
into a lymphocyte and non-
lymphocyte fraction by
MACS. Basophils were
double stained for CD49b
and FceRIa. Macrophages,
dendritic cells, neutrophils,
eosinophils, B cells and T
cells were stained for F4/80,
CD11c, Gr-1, Siglec-F,
CD19 and CD3e,
respectively. The respective
populations were gated and
displayed in histogram
plots. The black graph
represents Mcpt5-Cre
ROSA26-EYFP double
transgenic mice, the shaded
graph represents the
Cre-negative but ROSA26-
EYFP-positive control
(littermates in most
instances)
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123in vivo. We employed BAC transgene technology to
express a Cre cassette under the control of the Mcpt5
promoter. To our knowledge, this is the ﬁrst report of
mast cell-speciﬁc Cre-mediated recombination in the
mouse.
To date, important insights into functions of mast
cells have been gained by reconstitution of mast cell-
deﬁcient mice with mast cells differentiated in vitro
from gene deﬁcient bone marrow or embryonic and
hematopoietic stem cells (Galli et al. 2005b; Grimb-
aldeston et al. 2005; Kitamura et al. 1978; Tsai et al.
2005). While this model yielded important informa-
tion, inherent technical problems limit experi-
mentation and interpretation of data in this system
(Tsai et al. 2005). We expect that mast cell-speciﬁc
knock out of genes using our new Cre transgenic line
will greatly facilitate investigation of mast cell
biology.
The two Cre transgenic lines demonstrate that the
Mcpt5-promoter allows efﬁcient and cell type-spe-
ciﬁc expression of a Cre transgene inserted into the
ﬁrst exon. One animal of the line A-Mcpt5-Cre
(characterized by autosomal transgene inheritance)
showed non-speciﬁc Cre-mediated recombination in
non-mast cells while seven animals of this line did
not. This ﬁnding likely reﬂects accidental early
activity of the transgenic Mcpt5 promoter, e.g. in
one stem cell during the embryonic four cell stage.
Future analysis will deﬁne the frequency of such
events more precisely. In females of the X-Mcpt5-
Cre line (X-chromosomal inheritance), Cre-mediated
recombination occurred in only about half of the mast
cells due to inactivation of the transgene-carrying X-
chromosome. Incomplete inactivation of particular
genes may be advantageous if the attenuation of a
severe phenotype is desired.
Cre recombinase has been shown to mediate
genotoxicity in some Cre transgenic or Cre knock
in mouse strains resulting in a reduced proliferative
potential or even death of Cre expressing cells
(Schmidt-Supprian and Rajewsky 2007). In Mcpt5-
Cre mice, however, we found no difference in mast
cell numbers or proliferation of mast cells ex vivo in
response to stem cell factor indicating that Cre-
mediated genome damage is not a prominent feature
of these mice.
We are currently reﬁning our system further to
achieve also inducible mast cell-speciﬁc gene inac-
tivation in adult mice. In addition, we are breeding
the new lines to iDTR mice (Buch et al. 2005) aiming
at diphtheria toxin-inducible ablation of the mast cell
lineage in adult animals.
Fig. 4 Numbers and proliferative potential of peritoneal mast
cells in Mcpt5-Cre transgenic mice. (a) Mast cells were
quantiﬁed in peritoneal lavage ﬂuid from control (n = 9) and
Mcpt5-Cre (7 A-Mcpt5-Cre and 3 male X-Mcpt5-Cre) mice.
Mast cells were detected as CD117
+FceRIa
+ cells by FACS.
(b) Total cells from peritoneal lavage ﬂuid from one control
and one A-Mcpt5Cre ROSA26-EYFP double transgenic mouse
were incubated in complete Opti-MEM supplemented with 4%
supernatant from CHO transfectants secreting murine SCF
(Malbec et al. 2007). The CHO transfectants were generated by
S. Lyman, Immunex, Seattle and were kindly provided by
P. Dubreuil. Cell numbers were quantiﬁed at each passage
every 3–4 days by counting trypan blue-excluding cells
Transgenic Res (2008) 17:307–315 313
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